Immune Modulation and Efficacy of Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis in Lung Transplant Recipients During the Omicron Wave DOI Open Access

Lolita Sasset,

Roberta Angioni,

Nicolò Presa

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(8), P. 3696 - 3696

Published: April 14, 2025

Lung transplant recipients are at increased risk of severe COVID-19 due to lifelong immunosuppressive therapy, which impairs both innate and adaptive immune responses. Identifying effective supportive therapies is essential for mitigating the heightened vulnerability this population. This study investigated effects tixagevimab/cilgavimab, a monoclonal antibody as pre-exposure prophylaxis (PrEP) in A prospective was conducted on 19 lung Padua University Hospital, Italy, during Omicron variant wave (May–June 2022). Participants received tixagevimab/cilgavimab intramuscularly were monitored 180 days. SARS-CoV-2-specific levels measured baseline (T0), one month (T1), three months (T3) post-treatment. Cytokine profiles clinical outcomes, including SARS-CoV-2 infections, also assessed. At baseline, 50% patients had negative responses, but one-month post-treatment, all exceeded 700 kBAU/mL (median 3870 kBAU/mL), with decreasing remaining positive 1670 kBAU/mL). Remarkably, higher level circulating IL-18 found T3 comparison T0 who did not experience after PrEP. finding aligns IL-18’s primary role stimulating type-1 T helper (Th1) cell necessary induction virus-specific cytotoxic lymphocytes (CTLs). These results suggest that may induce systemic signature could contribute priming response against SARS-CoV-2, potentially mediated by interactions subsets.

Language: Английский

Immune Modulation and Efficacy of Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis in Lung Transplant Recipients During the Omicron Wave DOI Open Access

Lolita Sasset,

Roberta Angioni,

Nicolò Presa

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(8), P. 3696 - 3696

Published: April 14, 2025

Lung transplant recipients are at increased risk of severe COVID-19 due to lifelong immunosuppressive therapy, which impairs both innate and adaptive immune responses. Identifying effective supportive therapies is essential for mitigating the heightened vulnerability this population. This study investigated effects tixagevimab/cilgavimab, a monoclonal antibody as pre-exposure prophylaxis (PrEP) in A prospective was conducted on 19 lung Padua University Hospital, Italy, during Omicron variant wave (May–June 2022). Participants received tixagevimab/cilgavimab intramuscularly were monitored 180 days. SARS-CoV-2-specific levels measured baseline (T0), one month (T1), three months (T3) post-treatment. Cytokine profiles clinical outcomes, including SARS-CoV-2 infections, also assessed. At baseline, 50% patients had negative responses, but one-month post-treatment, all exceeded 700 kBAU/mL (median 3870 kBAU/mL), with decreasing remaining positive 1670 kBAU/mL). Remarkably, higher level circulating IL-18 found T3 comparison T0 who did not experience after PrEP. finding aligns IL-18’s primary role stimulating type-1 T helper (Th1) cell necessary induction virus-specific cytotoxic lymphocytes (CTLs). These results suggest that may induce systemic signature could contribute priming response against SARS-CoV-2, potentially mediated by interactions subsets.

Language: Английский

Citations

0